AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: Correction of murine ApoA-I deficiency

Journal of Gene Medicine

Volumn 11, Issue 8, 2009, Pages 697-707

  Vaessen, Stefan F C ^a   Veldman, Robert Jan ^a   Cornijn, Elisabeth M ^b   Snapper, Jolanda ^b   Sierts, Jeroen A ^a   van den Oever, Karin ^a   Beattie, Stuart G ^b   Twisk, Jaap ^b   Kuivenhoven, Jan Albert ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Amsterdam Molecular Therapeutics ^*  (Netherlands)

Author keywords

Adeno associated virus; Apolipoprotein A I; Gene therapy; HDL; Hypoalphalipoproteinemia

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; CAPSID PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE EXPRESSION; GENE THERAPY; LIPOPROTEIN DEFICIENCY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTICLE SIZE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; WEIGHT GAIN;

ANIMALS; APOLIPOPROTEIN A-I; BODY WEIGHT; CHOLESTEROL, HDL; CYTOMEGALOVIRUS; DEPENDOVIRUS; ENHANCER ELEMENTS, GENETIC; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MICE; MUTAGENESIS, INSERTIONAL; ORGAN SPECIFICITY; PHENOTYPE; PLASMIDS; PROMOTER REGIONS, GENETIC; SEROTYPING; WEIGHT GAIN;

ADENO-ASSOCIATED VIRUS; CYTOMEGALOVIRUS; MIRIDAE; MURINAE; MUS;

EID: 70349489996     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1344     Document Type: Article

References (47)

1. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105: 290-292.
2. Hovingh GK, Brownlie A, Bisoendial RJ, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 2004; 44: 1429-1435.
3. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr. Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 1982; 2: 16-26.
4. Forte TM, Nichols AV, Krauss RM, Norum RA. Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis. J Clin Invest 1984; 74: 1601-1613.
5. Belalcazar LM, Merched A, Carr B, et al. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 2003; 107: 2726-2732.
6. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100: 1816-1822.
7. Lebherz C, Sanmiguel J, Wilson JM, Rader DJ. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol 2007; 6: 15-22.
8. Oka K, Belalcazar LM, Dieker C, et al. Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector. Gene Ther 2006; 14: 191-202.
9. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
10. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 2008; 15: 858-863.
11. Golder-Novoselsky E, Nichols AV, Rubin EM, Forte TM. Human apo A-I in transgenic mice is more efficient in activating lecithin: cholesterol acyltransferase than mouse apo A-I. Biochim Biophys Acta 1995; 1254: 217-220.
12. Harding TC, Koprivnikar KE, Tu GH, et al. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B. Gene Ther 2004; 11: 204-213.
13. Miao CH, Ohashi K, Patijn GA, et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther 2000; 1: 522-532.
14. Kramer MG, Barajas M, Razquin N, et al. In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther 2003; 7: 375-385.
15. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541.
16. Nathwani AC, Gray JT, Ng CY, et al. Self complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006; 107: 2653-2661.
17. Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1-6. Mol Ther 2003; 7: 839-850.
18. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854-11859.
19. Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999; 6: 973-985.
20. Levels JH, Abraham PR, van den EA, van Deventer SJ. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun 2001; 69: 2821-2828.
21. Rip J, Nierman MC, Sierts JA, et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther 2005; 16: 1276-1286.
22. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
23. Ferreira V, van Dijk KW, Groen AK, et al. Macrophage-specific inhibition of NF-kappaB activation reduces foam-cell formation. Atherosclerosis 2007; 192: 283-290.
24. Polyak S, Mah C, Porvasnik S, et al. Gene delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno-associated virus types 1, 2 and 5. Dig Dis Sci 2008; 53: 1261-1270.
25. During MJ, Xu R, Young D, Kaplitt MG, Sherwin RS, Leone P. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med 1998; 4: 1131-1135.
26. Xiao W, Berta SC, Lu MM, Moscioni AD, Tazelaar J, Wilson JM. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 1998; 72: 10222-10226.
27. Loeb JE, Cordier WS, HarrisME, Weitzman MD, Hope TJ. Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. Hum Gene Ther 1999; 10: 2295-2305.
28. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003; 10: 2112-2118.
29. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003; 10: 2105-2111.
30. Thomas CE, Storm TA, Huang Z, Kay MA. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 2004; 78: 3110-3122.
31. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009; 199: 381-390.
32. Benoit P, Emmanuel F, Caillaud JM, et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation 1999; 99: 105-110.
33. Van Linthout S, Lusky M, Collen D, De Geest B. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector. Gene Ther 2002; 9: 1520-1528.
34. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002; 76: 4580-4590.
35. McCaffrey AP, Fawcett P, Nakai H, et al. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther 2008; 16: 931-941.
36. Sharifi BG, Wu K, Wang L, Ong JM, Zhou X, Shah PK. AAV serotype-dependent apolipoprotein A-I Milano gene expression. Atherosclerosis 2005; 181: 261-269.
37. Kitajima K, Marchadier DH, Burstein H, Rader DJ. Persistent liver expression of murine apoA-1 using vectors based on adeno-associated viral vectors serotypes 5 and 1. Atherosclerosis 2005; 186: 65-73.
38. Davidoff AM, Ng CY, Spence Y, Nathwani AC. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 2003; 102: 480-488.
39. Wu Z, Sun J, Zhang T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 2008; 16: 280-289.
40. Nathwani AC, Cochrane M, McIntosh J, et al. Enhancing transduction of the liver by adeno-associated viral vectors. Gene Ther 2009; 16: 60-69.
41. Plump AS, Azrolan N, Odaka H, et al. ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes. J Lipid Res 1997; 38: 1033-1047.
42. Li H, Reddick RL,Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993; 13: 1814-1821.
43. Williamson R, Lee D, Hagaman J,Maeda N. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci USA 1992; 89: 7134-7138.
44. Zabalawi M, Bhat S, Loughlin T, et al. Induction of fatal inflammation in LDL receptor and ApoA-I double-knockout mice fed dietary fat and cholesterol. Am J Pathol 2003; 163: 1201-1213.
45. Plump AS, Erickson SK, Weng W, Partin JS, Breslow JL, Williams DL. Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production. J Clin Invest 1996; 97: 2660-2671.
46. De Geest BR, Van Linthout SA, Collen D. Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells. Blood 2003; 101: 2551-2556.
47. Gao G, Lu Y, Calcedo R, et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 2006; 13: 77-87.